Sonye Danoff, MD
Enriched profileProfessor of Medicine; Director, Johns Hopkins Interstitial Lung Disease/Pulmonary Fibrosis Program · Johns Hopkins Medicine
Sonye Danoff is Professor of Medicine; Director, Johns Hopkins Interstitial Lung Disease/Pulmonary Fibrosis Program at Johns Hopkins Medicine. OpenAlex indexes 212 publications with 18,945 citations (h-index 63); ClinicalTrials.gov lists 1 registered study with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Pulmonary Disease profiles in the findmyKOL directory.
Data verified 9 Oct 2026
Overview
Updated 15 Oct 2026
Sonye Danoff, M.D., is Professor of Medicine at Johns Hopkins Medicine. The public record shows 212 publications with 18,945 citations (h-index 63), centered on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Systemic Sclerosis and Related Diseases, Inflammatory Myopathies and Dermatomyositis. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 8 companies, 1 NIH-funded awards (2001–2005).
- Most recent indexed publication: 2026 · medRxiv
- Top research focus: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 128.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest
Sponsor: Johns Hopkins University
Industry payments
Updated 15 Oct 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202511 payments$13,756openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Boehringer Ingelheim International GmbHProgram year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.2%Kinase inhibitor32.1%Ofev100%Part D<11 patientsPurine Antimetabolite11.4%Azathioprine100%Part D≥12 patients+ 1 more class in this area
Metabolism & gastrointestinal
34.6%Corticosteroid24.8%Prednisone100%Part D≥22 patientsProton pump inhibitor5.3%Omeprazole100%Part D<11 patients+ 1 more class in this area
Anti-infectives
10.6%Macrolide Antimicrobial6.1%Azithromycin100%Part D<11 patientsShort-acting sulfonamides4.5%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 15 Oct 2026
1 NIH research award on record, funded 2001–2005 per NIH RePORTER. The latest:
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Abatacept for the treatment of myositis-associated interstitial lung disease.
Rheumatology (Oxford, England)
Clinical Trial2025 - Practice Patterns for Screening and Treating Interstitial Lung Disease-related Pulmonary Hypertension at Specialty Care Centers in the United States.
Annals of the American Thoracic Society
Letter2024 - Human Leukocyte Antigen Alleles Associated with Interstitial Lung Disease in North Americans with Idiopathic Inflammatory Myopathy.
American journal of respiratory and critical care medicine
Letter2023 - Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement.
American journal of respiratory and critical care medicine
Article2021
Most-cited works
by citation count (OpenAlex)- 01Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice GuidelineArticle4,092 citations2018
- 02
- 03Short telomeres are a risk factor for idiopathic pulmonary fibrosisArticle806 citations2008
- 04
- 05Interstitial Lung Disease Associated With the Idiopathic Inflammatory MyopathiesArticle564 citations2010
Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hopkinsmedicine.org ↗
Secondary affiliations
appointments beyond the home institution- Associate Director
Johns Hopkins Myositis Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rareshare.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital